XML 93 R69.htm IDEA: XBRL DOCUMENT v3.25.3
Subsequent Event (Details)
$ / shares in Units, $ in Thousands
9 Months Ended
Oct. 14, 2025
USD ($)
$ / shares
Oct. 08, 2025
USD ($)
Jul. 24, 2025
USD ($)
Apr. 18, 2025
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Oct. 01, 2025
USD ($)
Subsequent Event [Line Items]              
Prepayment premium and fees on Pharmakon term loan         $ 3,802 $ 0  
Pharmakon Advisors, LP | Line of Credit              
Subsequent Event [Line Items]              
Prepayment premium and fees on Pharmakon term loan     $ 50,000 $ 75,000      
Prepayment premium     1,500 2,250      
Interest expense     $ 376 $ 424      
Disposal Group, Held-for-Sale, Not Discontinued Operations | BioCryst Ireland | Forecast              
Subsequent Event [Line Items]              
Upfront consideration to be received             $ 250,000
Contingent consideration to be received             14,000
Royalty release fee             $ 15,000
Subsequent Event | Astria              
Subsequent Event [Line Items]              
Conversion ratio 0.59            
Price per share (in usd per share) | $ / shares $ 8.55            
Subsequent Event | Pharmakon Advisors, LP | Line of Credit              
Subsequent Event [Line Items]              
Prepayment premium and fees on Pharmakon term loan   $ 198,704          
Prepayment premium   5,961          
Interest expense   $ 485          
Subsequent Event | Blackstone | Line of Credit | Secured Debt              
Subsequent Event [Line Items]              
Debt instrument, face amount $ 550            
Proceeds from issuance of long-term debt 350            
Maximum aggregate principal amount 50            
Subsequent Event | Blackstone | Line of Credit | Unsecured Debt              
Subsequent Event [Line Items]              
Maximum aggregate principal amount $ 150